Below you will find news and press releases from industry, government, and academia regarding product developments and medical/scientific research news.
Urinary stress incontinence (USI) affects 25 per cent of women over 40 with the incidence increasing with age. It’s defined as a loss of urine often with cough, sneeze, laughing, running or lifting. Yet despite the prevalence of this condition, many women do not seek help until symptoms become severe and have been ongoing for at least two years. Factors contributing to USI are childbirth, pregnancy, menopause, low back pain, weight gain and smoking. USI responds well to conservative non-surgical treatment with the first line of treatment often being pelvic floor strengthening exercises under the supervision of a physiotherapist. Physiotherapists often use biofeedback and electrical stimulation to help reeducate these muscles. Read more.
Source: The Chronicle Herald, February 8, 2017
You are invited to participate in a paid market research study about your personal experience with underactive bladder (UAB), which may also be known as impaired bladder emptying, hypotonic/flaccid bladder, detrusor underactivity/failure, voiding dysfunction, or chronic/acute urinary retention. The market research firm conducting the study would like to understand more about your personal journey and discuss potential new diagnostic and treatment options. In order to participate, you must have been diagnosed with UAB. The study consists of a 45-minute phone interview that will require internet access, and you will be compensated $100 for your time. If you are interested in participating, please click this link to see if you qualify: https://hub.m3globalresearch.com/page/r13650tdip.cfm This study is being managed by ZS, an Independent Research Firm, in compliance with marketing research standards. The study concludes on February 8, 2017.
As our aging population grows, nurses are continuing to see more instances of tough-to-manage skin breakdown due to incontinence. Skin damage associated with urine and/or fecal exposure, otherwise known as incontinence associated dermatitis (IAD), is a resource-intensive condition that can be very painful for patients. To help combat this debilitating problem, 3M introduces its revolutionary 3M™ Cavilon™ Advanced Skin Protectant, a high endurance skin protectant designed to stop, reverse and prevent the damaging effects of moderate to severe IAD. The new skin protectant provides clinicians with an easier, more effective way to manage patients with IAD to help improve their quality of life and overall patient experience. Read more.
Source: Business Wire, February 1, 2017
The American Urological Association (AUA) and the Urology Care Foundation, together with the Bladder Health Alliance – a coalition of groups representing physicians, patients and veterans – applauded Congressman Eliot Engel (NY-16) for his introduction of House Resolution 67, a measure supporting the designation of November 2017 as “National Bladder Health Month.” Read more.
Source: PRNewswire, January 30, 2017
A newly approved drug may help in the battle against Clostridium difficile — a potentially fatal “superbug” gut infection that has become a scourge in U.S. hospitals. In two clinical trials, researchers found that the drug, called bezlotoxumab (Zinplava), cut the risk of a recurrent C. difficile infection by almost 40 percent. That’s important, because the gut infection commonly comes back after treatment with antibiotics — around 20 percent of the time, according to the U.S. Centers for Disease Control and Prevention. Read more.
HealthDay News, January 25, 2017
Trulance (plecanatide) has been approved by the U.S. Food and Drug Administration to treat persistent constipation of unknown (idiopathic) cause in adults. Some 42 million people in the United States are affected by constipation, according to the National Institutes of Health. Once-daily Trulance is designed to stimulate the upper gastrointestinal tract to secrete fluid and “support regular bowel function,” the FDA said in a news release. Read more.
Source: HealthDay News, January 20, 2017
Axonics Modulation Technologies, Inc. announced today that it received a Homologation d’un instrument médical (medical device approval) for the first rechargeable Sacral Neuromodulation (r-SNM™) System® to treat Overactive Bladder (OAB), Fecal Incontinence and Urinary Retention. The Health Canada license confirms that the Axonics® product meets all of the Canadian Medical Devices Regulations, Section 36, for Active Implantable Medical Devices and enables Axonics to market its r-SNM System throughout Canada. Read more.
Source: Yahoo! Finance, January 5, 2017